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Chronic periodontitis results from a complex aetiology, including the formation of a 
subgingival biofilm and the elicitation of the host’s immune and inflammatory response. The 
hallmark of chronic periodontitis is alveolar bone loss and soft periodontal tissue destruction. 
Evidence supports that periodontitis progresses in dynamic states of exacerbation and 
remission or quiescence. The major clinical approach to identify disease progression is the 
tolerance method, based on sequential probing. 
Collagen degradation is one of the key events in periodontal destructive lesions. Matrix 
metalloproteinase (MMP)-8 and MMP-13 are the primary collagenolytic MMPs that are 
associated with the severity of periodontal inflammation and disease, either by a direct 
breakdown of the collagenised matrix or by the processing of non-matrix bioactive substrates. 
Despite the numerous host mediators that have been proposed as potential biomarkers for 
chronic periodontitis, they reflect inflammation rather than the loss of periodontal attachment. 
The aim of the present study was to determine the key molecular MMP-8 and -13 interactions 
in gingival crevicular fluid (GCF) and gingival tissue from progressive periodontitis lesions 
and MMP-8 null allele mouse model. 
In study (I), GCF and gingival biopsies from active and inactive sites of chronic periodontitis 
patients, which were determined clinically by the tolerance method, and healthy GCF were 
analysed for MMP-13 and tissue inhibitor of matrix metalloproteinases (TIMP)-1. Chronic 
periodontitis was characterised by increased MMP-13 levels and the active sites showed a 
tendency of decreased TIMP-1 levels associated with increments of MMP-13 and total protein 
 
 
concentration compared to inactive sites. In study (II), we investigated whether MMP-13 
activity was associated with TIMP-1, bone collagen breakdown through ICTP levels, as well 
as the activation rate of MMP-9 in destructive lesions. The active sites demonstrated 
increased GCF ICTP levels as well as lowered TIMP-1 detection along with elevated MMP-
13 activity. MMP-9 activation rate was enhanced by MMP-13 in diseased gingival tissue. In 
study (III), we analysed the potential association between the levels, molecular forms, 
isoenzyme distribution and degree of activation of MMP-8, MMP-14, MPO and the inhibitor 
TIMP-1 in GCF from periodontitis progressive patients at baseline and after periodontal 
therapy. A positive correlation was found for MPO/MMP-8 and their levels associated with 
progression episodes and treatment response. Because MMP-8 is activated by hypochlorous 
acid in vitro, our results suggested an interaction between the MPO oxidative pathway and 
MMP-8 activation in GCF. Finally, in study (IV), on the basis of the previous finding that 
MMP-8-deficient mice showed impaired neutrophil responses and severe alveolar bone loss, 
we aimed to characterise the detection patterns of LIX/CXCL5, SDF-1/CXCL12 and RANKL 
in P. gingivalis-induced experimental periodontitis and in the MMP-8-/- murine model. The 
detection of neutrophil-chemoattractant LIX/CXCL5 was restricted to the oral-periodontal 
interface and its levels were reduced in infected MMP-8 null mice vs. wild type mice, 
whereas the detection of SDF-1/CXCL12 and RANKL in periodontal tissues increased in 
experimentally-induced periodontitis, irrespectively from the genotype. Accordingly, MMP-8 
might regulate LIX/CXCL5 levels by undetermined mechanisms, and SDF-1/CXCL12 and 




Periodontal diseases result from the interplay of diverse aetiologic factors, including the 
formation of a complex biofilm in the subgingival microenvironment, social and behaviour 
modulations, genetic or epigenetic traits and the host’s immune and inflammatory response 
(Haffajee and Socransky, 1994). 
The hallmark of chronic periodontitis is alveolar bone loss and soft periodontal tissue 
destruction (Vernal et al., 2004). Evidence supports that periodontitis progresses in 
dynamic states of exacerbation and remission (Jeffcoat and Reddy, 1991). The most 
common method used to diagnose attachment loss and, thereby, the disease progression, is 
to record the clinical attachment at sequential examinations by periodontal probing (Reddy 
et al., 1997). Periodontal supporting tissue homeostasis depends on extracellular proteolysis 
and remodelling, involving a tight balance among protease activities and inhibitors. 
Unhampered proteolysis results in collagenous matrix breakdown and the loss of 
periodontal supporting tissue. Pathologically enhanced expression and activation of host 
matrix metalloproteinases (MMPs) over the protective shield provided by their main tissue 
inhibitors (TIMPs) is a well-characterised feature in chronic periodontitis (Sorsa et al., 
2006). Although MMPs have been assumed to primarily play a matrix degradative role, a 
broader substrate degradome has shown proteolytic susceptibility to MMPs, including 
cytokines, chemokines, other MMPs and apoptotic signals. As a result, MMPs can also 
modulate immune and inflammatory responses, among other cellular processes (Folgueras 
et al., 2004; Sorsa et al., 2004; Sorsa et al., 2006). 
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Collagen degradation is regarded as one of the key events in periodontal destructive lesions 
(Golub et al., 1997; Kiili et al., 2002). The major collagenolytic MMPs associated with the 
severity of periodontal inflammation and disease are collagenase-2 (MMP-8) and 
collagenase-3 (MMP-13); whereas collagenase-1 (MMP-1) is primarily related to 
physiological periodontal tissue turnover (Kiili et al., 2002; Makela et al., 1994; Sorsa et 
al., 1988; Sorsa et al., 2004; Sorsa et al., 2006; Tervahartiala et al., 2000; Uitto et al., 2003). 
Despite the fact that many potential biomarkers have been proposed in chronic 
periodontitis, most of them demonstrate limited usefulness because they reflect periodontal 
inflammation rather than disease progression (Loos and Tjoa, 2005). While numerous 
cross-sectional studies have shown evidence that MMP levels parallel the severity of 
periodontal inflammation, much less data are available from active periodontal destructive 
lesions assessed by longitudinal studies. Pathologically excessive collagenase levels and 
activities in progressive periodontitis-affected tissue and oral fluids might provide a 
proteolytic signature of the underlying biological phenotype that might contribute to the 
development of chair-side point of care diagnostics, in order to improve clinical follow-ups, 
treatment decisions and future drug development (Leppilahti et al., 2011; Mantyla et al., 
2003; Mantyla et al., 2006; Sorsa et al., 2004; Sorsa et al., 2006). The purpose of this study 
was to find the key molecular collagenolytic MMP-interactions/cascades in gingival 
crevicular fluid (GCF) and gingival tissue from destructive periodontitis lesions and MMP-
8 null allele mouse model that might be suitable for potential point-of-care/chair-side 
diagnostic development for chronic periodontitis. 
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2. REVIEW OF THE LITERATURE 
 
2.1 General aspects of periodontal health and disease 
2.11 Healthy periodontium 
The periodontium is defined as the tissues supporting and surrounding the tooth and 
corresponds to the root cementum, periodontal ligament, alveolar bone and gingiva. The 
gingiva part that faces the tooth is known as the dentogingival junction. The junctional 
epithelium is crucial among the components of the dentogingival junction because it seals 
off the rest of the periodontal tissues from the oral environment and represents the first line 
of defence, while structural alterations represent the first step towards the development of 
periodontal disease. The epithelial attachment corresponds to the layer of the junctional 
epithelium that faces the tooth, providing the actual attachment among them. Even in 
clinically normal circumstances, the connective tissue supporting the junctional epithelium 
shows an inflammatory cell infiltrate composed of neutrophils and T lymphocytes that is 
regarded to influence the overlying epithelial phenotype (Nanci and Bosshardt, 2006) 
(Figure 1.). 
 
2.12 Periodontal diseases 
Periodontal diseases usually refer to the common inflammatory disorders of gingivitis and 
periodontitis caused by pathogenic microbiota harvested in the biofilm or dental plaque that 
forms adjacent to the teeth. Gingivitis is an inflammatory condition of the gingiva. 
Gingivitis can be modified by several factors, such as smoking and hormonal changes, and 
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it clinically displays the typical cardinal signs of inflammation (Kinane, 2001). 
Periodontitis follows gingivitis and is influenced by the host’s immune and inflammatory 
responses. Periodontitis involves the irreversible destruction of the supporting tissues, 
including the periodontal ligament, alveolar bone and soft tissues; if left untreated, it often 
leads to tooth loss (Kinane, 2001; Socransky and Haffajee, 2005) (Figure 1.). However, not 
all gingivitis progresses towards periodontitis; in addition, periodontitis does not affect all 
teeth evenly, but it does have both a subject and site predilection. Furthermore, only 
relatively few sites undergo extensive periodontal destruction within a given observation 
period. 
Chronic periodontitis is the most common form of periodontitis; it occurs primarily in 
adults, and it is generally a slowly progressing disease that is associated with the presence 
of subgingival calculus. Overall, periodontal disease progression can be considered a 
continuous process that undergoes periods of exacerbation (Kinane, 2001).  
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Figure 1. Healthy periodontium versus periodontitis 
HM: bacterial microbiota in health; PM: Periodontopathogens; G: Gingiva; AB: Alveolar 
bone; PL: Periodontal ligament; L: Infiltrating leukocytes; OC: Osteoclast. 
 
2.2 Clinical model of disease progression 
 
Chronic periodontitis has been proposed to progress in both a slow continuous manner and 
in short bursts of disease activity, followed by periods of disease inactivity or quiescence 
(Goodson et al., 1982; Goodson et al., 1984; Loe et al., 1978; Socransky et al., 1984). 
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Accordingly, periodontal tissue support is lost during short, acute episodes of disease 
activity or “bursts”, followed by variable periods of quiescence. Thus, the longitudinal 
sequential examination of clinical attachment by periodontal probing is the most common 
clinical method to diagnose progressive periodontal disease (Reddy et al., 1997). 
The tolerance method has been the most prevalent clinical approach to determine site-
specific attachment level changes (Haffajee et al., 1983) because of its potential for early 
detection. The method is based on longitudinal clinical examinations and recording the 
attachment loss. Progression is defined as attachment loss ≥ 2 mm during a 2 -month period 
at the site level (active sites) and at least 2 active sites must be identified to consider the 
patient as undergoing disease progression. 
 
2.3 Etiopathogenesis of chronic periodontitis 
2.31 Dental plaque 
Bacterial biofilms represent the primary aetiological factor in the initiation of gingival 
inflammation and subsequent destruction of periodontal supporting tissues (Haffajee and 
Socransky, 1994). There is strong evidence that suggests that Aggregatibacter (A.) 
actinomycetemcomitans, Porphyromonas (P.) gingivalis and Tannerella (T.) forsythia are 
periodontal pathogens when they are present in sufficient numbers and in susceptible hosts 
(Consensus report. Periodontal diseases: pathogenesis and microbial factors, 1996). 
P. gingivalis is a gram-negative, black-pigmented, strictly anaerobic asaccharolytic bacteria 
that has previously been involved in periodontal disease progression (Holt et al., 1999). P. 
gingivalis produces an array of potential virulence factors (Yilmaz, 2008), such as 
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lipopolysaccharide (LPS), capsule polysaccharides, hemagglutinins, fimbriae and cysteine 
proteases known as “gingipains” (Hajishengallis, 2009). Despite the reported differences in 
the prevalence of periodontal pathogens among ethnically or geographically distinct 
populations, P. gingivalis has shown to be the most frequent periodontal pathogen 
associated with periodontitis in the Chilean population (Herrera et al., 2008; Lopez et al., 
2004). Additionally, significantly elevated levels and mean percentages of P. gingivalis 
have been reported in active periodontal lesions compared with inactive ones (Lopez, 2000; 
Silva et al., 2008) and have been suggested to predict disease progression (Byrne et al., 
2009). 
 
2.32 Host response: General considerations 
Although chronic bacterial exposure is a prerequisite for the occurrence of periodontal 
tissue destruction, its presence alone is not sufficient to explain disease initiation and 
progression (Grossi et al., 1994). In fact, the major component of soft- and hard- tissue 
destruction associated with periodontitis results from the activation of the host’s immune-
inflammatory response to the bacterial challenge (Gemmell et al., 2002). On the basis of 
histopathological features, infection induces vascular and cellular changes with the 
formation of an inflammatory infiltrate, destruction of alveolar bone and apical migration 
of junctional epithelium (Kinane, 2001). The inflammatory process developed in 
periodontitis may be divided into three phases: acute, immune response and the chronic 
phase (Offenbacher, 1996). The transition from gingival health to early inflammation is 
characterised by a local increase in vascular permeability, redness, swelling and the 
recruitment and activation of polymorphonuclear neutrophils (PMNs) (Delima and Van 
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Dyke, 2003). Posterior influx of macrophages and antigen-presenting cells present the 
foreign antigens to T lymphocytes during the subsequent immune response phase, followed 
by the expansion of antibody-secreting plasma cells resulting in the development of a 
chronic lesion (Gemmell and Seymour, 2004). As a result of immune activation, the active 
expression of osteolytic cytokines, such as interleukin (IL)-1β and tumour necrosis factor 
alpha (TNF)-α, stimulates the alveolar bone resorption and collagen destruction via tissue-
derived MMPs, a major pathway for the breakdown of bony and soft connective tissue 
associated with periodontal activity (Buduneli and Kinane, 2011; Offenbacher, 1996). 
 
2.4 Gingival crevicular fluid 
 
In physiologic conditions, gingival crevicular fluid (GCF) is a transudate composed of 
molecules derived from serum. Host cells from gingival tissue, inflammatory leukocytes 
and bacteria from subgingival plaque can be harvested non-invasively from the gingival 
sulcus. With the onset of inflammation, increased vascular and epithelial permeability 
permits the extravasation of high molecular proteins from general circulation and 
periodontal tissues; thus, GCF shifts to an inflammatory exudate (Adonogianaki et al., 
1996; Buduneli and Kinane, 2011; Curtis et al., 1990; Oringer et al., 2002). In healthy 
subjects and under resting conditions, GCF flow rates correspond to approximately 0.1 
μL/min per tooth, but these rates can increase up to fivefold in subjects affected by 
gingivitis and periodontitis (Curtis et al., 1990; Pisano et al., 2005; Uitto et al., 2003). 
During the disease, GCF contains molecules involved in the destructive process, and these 
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molecules show significant potential as a source of disease biomarkers that might reflect 
soft and hard tissue catabolism (Loos and Tjoa, 2005). 
 
2.5 Matrix metalloproteinases 
 
Matrix metalloproteinases (MMPs) are genetically distinct but structurally related zinc-
dependent metalloendopeptidases. MMPs degrade extracellular matrix and further 
potentiate proteolysis and inflammation by processing bioactive non-matrix substrates, 
such as cytokines, chemokines and growth factors, and by activating other MMPs 
(Folgueras et al., 2004; McQuibban et al., 2001; McQuibban et al., 2002; Overall et al., 
2002; Sorsa et al., 2004; Sorsa et al., 2006). MMPs share a similar basic structure 
composed of three domains, the pro-peptide, catalytic and the hemopexin-like domain 
(Kessenbrock et al., 2010). The 23 MMPs expressed in humans can be classified into 
different subgroups based on their primary structures and substrate specificities: 
collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9), membrane-type MMPs 





Figure 2. Structural classification of MMPs 
Reproduced with permission from The International Journal of Developmental Biology 
2004;48:411-24 (Folgueras et al., 2004). 
 
2.51 Regulation of MMP activity 
MMP proteolytic activity is subjected to a complex regulation through gene expression, 
compartmentalisation, and zymogen conversion, as well as the action of specific inhibitors. 
MMPs are initially expressed in an enzymatically inactive state because of the interaction 
of a cysteine residue of the pro-domain with the zinc ion of the catalytic site. The disruption 
of this interaction (cysteine switch) by proteolytic removal or chemical modification results 
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in enzyme activation. There are several proteinase cascades that mediate and amplify MMP 
activation, such as plasmin, furin and active MMPs, as well as chemical activators, such as 
reactive oxygen species (ROS) (Kessenbrock et al., 2010; Sorsa et al., 1992; Weiss et al., 
1985). Once activated, the most important physiological inhibitors are tissue inhibitors of 
MMPs (TIMPs) -1, -2, -3 and -4 (Kessenbrock et al., 2010), Thus, the pathophysiological 
significance of increased MMP expression in periodontitis will rely on their regulation by 
activating enzymes or compounds and endogenous inhibitors. 
 
2.52 Collagenolytic MMP involvement in chronic periodontitis 
Pathologically enhanced expression and activation of host MMPs over the protective shield 
provided by their TIMPs induced by bacterial infection and cytokines is a well 
characterised feature in chronic periodontitis. Many inflammatory mediators have been 
proposed as potential biomarkers, including MMPs; however, most of them demonstrate 
limited usefulness because they reflect periodontal inflammation rather than disease 
progression (Loos and Tjoa, 2005; Sorsa et al., 2006). Because type I collagen is the 
primary extracellular matrix component of soft and hard periodontal tissues, collagen 
degradation is one of the key factors in uncontrolled destructive lesions, driving the 
attention towards collagenolytic MMPs (Golub et al., 1997). The determination of MMP 
levels and activities in disease progression may aid in the identification of susceptible sites 
and individuals under the risk of developing periodontal attachment loss. 
Five decades ago, the first collagenolytic enzyme was discovered (Gross and Lapiere, 
1962), and it was promptly identified in human gingiva (Fullmer and Gibson, 1966; Gibson 
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and Fullmer, 1966) and GCF (Golub et al., 1976) in association with the degree and 
severity of gingival inflammation (Overall and Sodek, 1987). Since then, growing evidence 
has supported that collagenases along with other cooperative MMPs play a central role in 
periodontal tissue destruction (Sorsa et al., 2004). The major collagenolytic MMPs 
associated with the severity of periodontal inflammation and disease are collagenase-2 
(MMP-8) and collagenase-3 (MMP-13), whereas collagenase-1 (MMP-1) is more related to 
periodontal tissue turnover under physiological conditions (Kiili et al., 2002; Makela et al., 
1994; Sorsa et al., 1988; Sorsa et al., 2004; Sorsa et al., 2006; Tervahartiala et al., 2000; 
Uitto et al., 2003). GCF MMP-8 accounts for the bulk of collagenases, followed by MMP-
13 (Golub et al., 1997; Golub et al., 2008). During periodontal inflammation, latent 
proMMPs might become active by the cooperative action of other MMPs, such as MMP-
14, ROS and microbial proteases (Holopainen et al., 2003; Ilgenli et al., 2006; Knauper et 
al., 1996; Leeman et al., 2002). 
A reduction in GCF total collagenase activity has been associated with the improvement of 
clinical parameters and the decrease of bone resorption fragment carboxyterminal 
telopeptide of type I collagen (ICTP) in subantimicrobial dose doxycycline (SDD)-treated 
post-menopausal women exhibiting periodontitis and systemic osteopenia during a two-
year follow-up period (Golub et al., 2008). This finding supports a role for collagenases in 
bone loss and thus in disease progression, which can be reflected in GCF. 
Despite the genetic background underlying periodontal diseases, MMP-1, -2, -9 and -13 
gene polymorphisms studies undergone in different ethnic populations have been conducted 
without finding any associations with the susceptibility to chronic periodontitis, except for 
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the MMP-1 polymorphic allele forms (Chen et al., 2007; Pirhan et al., 2008; Pirhan et al., 
2009; Ustun et al., 2008). 
 
2.53 MMP-8 in periodontal destructive lesions 
Matrix metalloproteinase-8 (MMP-8) is the major collagenolytic MMP in GCF, and 
elevated levels have been widely associated with the severity of periodontal inflammation 
and disease (Emingil et al., 2004; Kiili et al., 2002; Kinane et al., 2003; Mantyla et al., 
2003; Sorsa et al., 2006; Sorsa et al., 2010). MMP-8 not only degrades the primary 
extracellular matrix components of the periodontium, but also regulates the immune 
response; MMPs influence the bioavailability and biological activity of cytokines by 
proteolytic processing of non-matrix bioactive molecules, thus modifying their biological 
activity or levels (Gutierrez-Fernandez et al., 2007; Nilsson et al., 2009). 
The elevation of active MMP-8 has been previously associated with the conversion of 
gingivitis to periodontitis and the progression of established periodontitis (Lee et al., 1995; 
Mantyla et al., 2006; Romanelli et al., 1999). Repeatedly elevated GCF MMP-8 
concentrations determined by longitudinal monitoring of periodontal responses during the 
maintenance phase after scaling and root planning (SRP) were reported to be associated 
with a lack of improvement in clinical parameters (Mantyla et al., 2006). Additionally, 
increases in MMP-8 and IL-1β during the first year of periodontal maintenance have been 
reported to be associated with increased odds of subsequent attachment loss; whereas 
elevated levels of pyridinoline cross-linked ICTP at baseline resulted in increased odds of 
alveolar bone density and height loss driven primarily by a placebo group related to SDD 
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adjunctive therapy experimental group. No associations were found between MMP-8 levels 
and bone loss (Reinhardt et al., 2010). Overall, MMP-8 levels could reflect soft periodontal 
tissue destruction and periodontal response to treatment (Sorsa et al., 2010). 
In spite of the well-known association between high MMP-8 levels and periodontitis, its 
biological functions are not completely clear (Gutierrez-Fernandez et al., 2007). MMP-8 
deficient mouse models reveal an impaired inflammatory response, characterised by 
abnormal neutrophil infiltration and expression of cytokines, such as transforming growth 
factor (TGF)-β (Gutierrez-Fernandez et al., 2007; Korpi et al., 2009). The recent 
development of the P. gingivalis-induced periodontitis MMP-8-deficient mice model 
unexpectedly showed extensive alveolar bone resorption (Kuula et al., 2009). 
Additionally, the destructive periodontal disease has been associated with and increased 
risk of cardiovascular complications. Recently, MMP-8 has been implicated in 
atherosclerotic plaque destabilisation by the thinning of the protective fibrous cap (Herman 
et al., 2001). P. gingivalis-induced experimental periodontitis in MMP-8 null mice have 
altered lipoprotein profiles, compared with wild types (Kuula et al., 2009). Similarly, A. 
Actinomycetemcomitans-infected mice displayed proatherogenic lipoprotein profiles, 
increased C-reactive protein (CRP), MMP-9 and lipid metabolism in serum of 
Apolipoprotein E-deficient mice, known to promote the development of atherosclerosis 
(Tuomainen et al., 2008). 
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2.54 MMP-13 in periodontal destructive lesions 
MMP-13 was first cloned from breast carcinoma (Freije et al., 1994) and is considered to 
play an important role in skeletal biology (Stahle-Backdahl et al., 1997). MMP-13 is 
expressed by sulcular epithelial cells, endothelial cells, macrophage-like cells, fibroblasts, 
plasma cells and osteoblasts (Hernandez et al., 2006; Nakamura et al., 2004; Rydziel et al., 
2000). Longitudinal studies in progression of chronic periodontitis, which was addressed 
clinically by the tolerance method, demonstrated that active sites had significantly elevated 
MMP-13 activity (Hernandez et al., 2006). On the basis of these data, MMP-13 might be 
associated with the progression of periodontal attachment loss. 
Evidence suggests that MMP-13 might initiate bone resorption by activating osteoclasts 
(Holliday et al., 1997) and proMMP-9 in vitro (Knauper et al., 1997b). Active MMP-9 
further digests denatured collagen derived from MMP-13 activity (Hill et al., 1995) and is 
thought to act over preosteoclast recruitment as well as to activate proMMP-13 and 
proMMP-2. Additionally, proMMP-13 can also be activated in vitro by active MMP-14, 
MMP-13 and MMP-2 (Knauper et al., 1996). Soluble forms of all of these MMPs have 
been described in periodontitis GCF and gingival tissue (Ilgenli et al., 2006; Tervahartiala 




Neutrophil-derived myeloperoxidase (MPO) is contained in primary (azurophilic) granules 
from neutrophils (Kowolik and Grant, 1983) and catalyses the formation of hypochlorous 
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acid (HOCl), a powerful antibacterial agent, which reflects the strength of oxidative stress 
(Wei et al., 2004). 
MPO GCF levels have previously been associated with the severity of periodontitis (Wei et 
al., 2004). Similarly, MMP-8 and MMP-9 are primarily released from neutrophils in a 
latent form and can be induced and activated during periodontal inflammation by host 
inflammatory mediators, such as TNF-α, IL-1β, ROS and MPO-produced hypochlorous 
acid (Saari et al., 1990), as well as microbial and host-derived proteases (Sorsa et al., 1992). 
MPO can inactivate pathogenic microbes by generating reactive oxygen species, 
oxidatively activate latent proMMP-8 and -9, as well as inactivate TIMPs (Saari et al., 
1990; Spallarossa et al., 2008; Wang et al., 2007). Thus, MPO can also oxidatively 
potentiate MMP-cascades in periodontal tissue destruction, becoming potentially 




Cytokines are soluble proteins that bind to specific receptors on target cells; they have 
transient expression and pleiotropic effects on target cell types. They play a fundamental 
role in inflammatory diseases, such as periodontitis (Preshaw and Taylor, 2011). The 
progression of periodontitis and its clinical outcome depend on the host’s immune 
response, leading to the recruitment of inflammatory cells, the generation of cytokines, the 
activation of osteoclasts (Seymour et al., 1993) and collagen destruction via tissue-derived 
matrix metalloproteinases (Offenbacher, 1996). 
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Cytokines regulate MMP expression. MMPs influence in turn the immune response 
regulating the biological activity of cytokines via proteolytic processing of non-matrix 
bioactive molecules (Sorsa et al., 2004; Tester et al., 2007; Van Lint et al., 2005). 
Furthermore, recent reports have demonstrated changes in cytokine levels associated with 
MMP expression and activity (Gutierrez-Fernandez et al., 2007; Nilsson et al., 2009). 
Chemokines are a superfamily of structurally related chemoattractant cytokines that direct 
the migration of leukocytes, regulate inflammation and cell trafficking. Among them, two 
primary families are classified based on the spacing of the first two cysteine residues: (1) 
the CXC chemokine family, such as IL-8/CXCL8, mouse lipopolysaccharide (LPS)-
induced CXC chemokine (LIX/CXCL5) and stromal-derived factor (SDF)-1/CXCL12; and 
(2) the CC chemokine family, which include the monocyte chemoattractant proteins 
(MCP)-1 to -4. In general terms, CXC chemokines attract PMN during the initial phases of 
inflammation, whereas CC chemokines target multiple leukocyte subsets (McQuibban et 
al., 2001; McQuibban et al., 2002). 
 
2.71 Mouse lipopolysaccharide (LPS)-induced CXC chemokines 
PMN are strategically localised between the bacterial biofilm and the junctional epithelium, 
where they represent the first line of defence among all leukocytes (Moughal et al., 1992; 
Tonetti et al., 1998). It is generally accepted that PMN contribute to a protective response 
against subgingival plaque, maintaining the integrity of attachment apparatus, whereas 
alterations in neutrophil function are associated with severe periodontal disease phenotypes 
(Kebschull et al., 2009). Mouse lipopolysaccharide (LPS)-induced CXC chemokine 
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(LIX/CXCL5) is the most abundant and potent murine chemoattractant for neutrophils in 
vitro and in vivo, representing the sole homologue of two closely related human 
chemokines, CXCL5 and CXCL6 (Kebschull et al., 2009; Kornman et al., 1997; Ruddy et 
al., 2004). 
MMP-8 deficient mice have shown decreased levels of PMN infiltration resulting from 
reduced LIX/CXCL5 mobilisation from the extracellular matrix (Van Lint et al., 2005). 
Recently, the differential expression of LIX/CXCL5 human homologue granulocyte 
chemotactic protein-2 (GCP-2/CXCL6) was reported to be upregulated in periodontal 
disease, which correlated positively with clinical parameters and periodontal pathogens 
(Kebschull et al., 2009). 
 
2.72 Stromal-derived factor-1 
Stromal-derived factor (SDF)-1/CXCL12 belongs to the CXC family of chemokines. 
Activation of its unique receptor CXCR4 is essential for its many functions, such as 
hematopoietic cell homing to bone marrow, promotion of chemotaxis, early development, 
cell function, bone resorption, aid in the survival of human osteoclasts and their monocytic 
precursors (in a manner similar to the early effects of the M-CSF+RANKL system), and 
enhance PMN migration. Recently, increased GCF SDF-1/CXCL12 levels have been 
associated with chronic periodontitis and periodontal tissue response to conventional 
treatment (Havens et al., 2008). 
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2.73 Receptor activator of NF-кB ligand 
The receptor activator of the NF-кB ligand (RANKL) is a crucial mediator required, along 
with the permissive colony stimulating factor (CSF)-1, for the full development of 
osteoclast precursors into mature multi-nucleated bone-resorbing cells (Fuller et al., 2007; 
Wright et al., 2005). RANKL exerts its biological effects directly through binding to its 
receptor RANK, inducing osteoclast differentiation, maturation, activation, and inhibiting 
their apoptosis (Lacey et al., 1998; Theill et al., 2002); whereas osteoprotegerin (OPG) is a 
decoy receptor that inhibits osteoclastogenesis through binding of RANKL (Simonet et al., 
1997). Inflammation and bone resorption during periodontitis have been widely associated 
with high RANKL levels and an augmented RANKL/OPG ratio (Vernal et al., 2006; 
Wright et al., 2005; Yu et al., 2003). Moreover, RANKL levels were found to be 
significantly higher in GCF from active sites versus inactive sites during progressive 
periodontitis (Vernal et al., 2004), suggesting its involvement in destructive periodontitis. 
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3. HYPOTHESIS AND AIMS OF THE STUDY 
 
Many potential biomarkers have been proposed in chronic periodontitis, but none of them, 
either alone or in combination, can be used to prevent irreversible periodontal breakdown. 
The characterisation of collagenolytic MMP levels and interactions in progressive 
periodontal lesions may aid in the development of chair-side point of care diagnostics, 
treatment decisions and future drug development. We propose that enhanced collagenase-
mediated proteolytic networks, involving enzyme activators, inhibitors and non-matrix 
bioactive substrates, are associated with chronic periodontitis progression in diseased 
periodontal tissues and are reflected in gingival crevicular fluid (GCF). Therefore, they 
might be utilised as potential biomarkers for disease progression. 
 
3.1 Aims of the study: 
 
1. To characterise the levels and relationships between MMP-13 to its major endogenous 
inhibitor TIMP-1 in GCF and gingival tissue from clinically progressive chronic 
periodontitis subjects and controls. 
2. To associate MMP-13 activity with levels of ICTP, TIMP-1 and MMP-9 activation 
rates in progressive chronic periodontitis. 
3. To identify potential oxidative (MPO) and proteolytic (MMP-14) interactions of MMP-
8 in GCF from clinically progressive chronic periodontitis at baseline and after 
conventional treatment. 
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4. To characterise the levels and tissue localisation patterns of potential cytokine MMP-8 
substrates in P. gingivalis-induced experimental periodontitis in MMP-8-/-mice v/s wild 
type (WT) mice.  
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4. MATERIALS AND METHODS 
 
4.1 Human studies (I-III) 
4.11 Study subjects (I-III) 
Patients with moderate to severe chronic periodontitis were enrolled in the study and were 
followed until they developed progression of the clinical disease. Patients were selected 
from the Center of Diagnostics and Treatment of Northern Metropolitan Health Services, 
Santiago. The inclusion criteria were a minimum of 14 natural teeth (excluding 3rd 
molars), at least 10 posterior teeth, at least 5-6 teeth had sites with probing depth ≥ 5mm, 
with attachment loss ≥ 3 mm and detectable bone loss via radiography; in addition, they 
must not have received previous periodontal treatment at the time of examination. 
Periodontally healthy volunteers also entered the study for control GCF collections. 
Exclusion criteria were as follows: history of systemic disorders, such as diabetes mellitus, 
osteoporosis and medications known to influence periodontal tissues, pregnancy or 
lactating females, and patient who had received antibiotic, anti-inflammatory, 
anticoagulant or hormonal drugs within the past six months prior to the study. 
4.12 Clinical examinations 
Probing depth (PD), clinical attachment loss (CAL), and dichotomous measurements of 
supragingival plaque accumulation (PA) and bleeding on probing from the base of the 
crevice (BOP) were recorded at six sites around the tooth. 
Disease activity was defined clinically by the tolerance method (Haffajee et al., 1983). At 
the site level, active sites exhibited attachment loss  ≥ 2.0 mm during the 2-month period. 
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Inactive sites were defined as those sites with probing depth and BOP equivalent to active 
sites, but without attachment loss during the same period. The patients were considered to 
undergo disease progression if they had a minimum of 2 active sites. Clinical parameter 
measurements were monitored at baseline, 2 and 4 months. 
When a patient was diagnosed as undergoing disease progression, GCF or gingival samples 
(when periodontal surgery was indicated) from both active and inactive sites were 
immediately taken at baseline and 2 months after treatment. Periodontal therapy consisted of 
scaling, root planning, and instruction of oral hygiene. The Institutional Reviews Board-
approved informed consent forms were signed by all of the study subjects. Upon the 
detection of disease progression, the patients immediately entered the treatment phase.  
4.13 Gingival crevicular fluid samples (I, II, III) 
After isolating the tooth with a cotton roll, supragingival plaque was removed, and GCF was 
collected for 30 s with paper strips (Proflow, Amityville, NY, USA). The volume of GCF was 
measured using a calibrated Periotron 8000 (Proflow, Amityville, NY, USA). GCF was 
extracted twice by centrifugation at 12.000 rpm for 5 min at 4°C in a standard volume of 
elution buffer containing 50 mM Tris-HCl pH 7.5, 0.2 M NaCl, 5 mM CaCl2 and 0.01% 
Triton X-100 and kept at -80°C, until MMP enzyme forms, activity and mediator levels were 
analyzed. 
4.14 Gingival tissue samples (I) 
An incision was made with a surgical blade through the gingival crevice to the alveolar crest. 
After washing, samples were homogenised in 0.15 M NaCl with a proteinase inhibitor 
cocktail (Roche Molecular Biochemicals, Mannheim, Germany), centrifuged at 13,000 x g for 
6 min at 4°C and kept under -80° until analysed for total levels of MMP-13 and TIMP-1. 
24 
4.15 Gingival explant cultures (II) 
Another group of gingival biopsies were prepared for explant cultures in 24-well plate with 
supplemented DMEM in a tissue/media ratio of 100:1 (w/v). After testing different MMP-13 
concentrations for 0.5-24 incubation hours, explant cultures were treated with or without 
recombinant MMP-13 (Chemicon, Temecula, California, USA) at a ratio of 1/3.000 (w/v) for 
1 h and 24 h and inactivated with 15 mM EDTA. Additional controls were made by adding 10 
µM CL-82198 (EMD Biosciences, San Diego, CA), a selective synthetic MMP-13 inhibitor, 
following the manufacturer’s recommendations. Culture supernatants were reserved for 
gelatine zymography assay. 
4.16 Determination of total protein concentration (I) 
Tissue homogenates and GCF total protein concentrations were measured by a Micro BCA 
kit (Pierce, Rockford, USA), following the manufacturer’s recommendations. Results were 
expressed as mg/mL of total protein content.  
4.17 Immunoblotting of MMP-8, MMP-13, MMP-14, MPO and TIMP-1 (I, III) 
MMP-8, MMP-14, MPO and TIMP-1 immunoreactivities in GCF and/or tissue 
homogenates were determined by immuno-Western blotting in non-reducing conditions 
using a specific rabbit polyclonal anti-human MMP-8 antibody (1:500 dilution as previously 
described), (Hanemaaijer et al., 1997; Sorsa et al., 1994; Sorsa et al., 1999; Tervahartiala et 
al., 2000), rabbit polyclonal anti-human MMP-14 antibody (1:500 dilution), (Biogenesis, 
Poole, England) and monoclonal anti-human MPO antibody (1:1000 dilution), (R&D 
Systems, Inc. Minneapolis, MN, USA). A positive control for MPO, consisting of 
recombinant protein, was added (R&D Systems, Inc. Minneapolis, MN, USA). Immuno-
Western blots were performed under reducing conditions using monoclonal anti-human 
25 
MMP-13 and TIMP-1 antibodies (Chemicon, Temecula, California, USA), which were both 
diluted 1:200. 
After confirming the mono specificity of MMP-13 and TIMP-1 antibodies by immuno-
Western blots, aliquots of GCF and tissue homogenates were applied in duplicates onto the 
PVDF membranes, while the following steps were performed as described for immuno-
Western blots. The quantification was conducted with a Bio-Rad model GS-700 Imaging 
Densitometer using the Quantity-One–program (Bio-Rad, Hercules, CA, USA). The results 
were expressed as arbitrary units (au/mL) and per mg of total protein. 
4.18 Determination of MMP-8, MPO, TIMP-1 and ICTP protein levels (II, III) 
MMP-8 protein levels were measured by a time-resolved immunofluorometric assay 
(Hanemaaijer et al., 1997). MPO was determined by enzyme-immunosorbent assay 
(Immundiagnostik AG, Bensheim, Germany) and TIMP-1 and MMP-8 additionally, by the 
Biotrak ELISA system (GE Healthcare, Amersham, Slough, Berkshire, UK). An enzyme 
immunoassay (EIA) was employed for measurement of ICTP levels (Orion Diagnostica, 
Espoo, Finland); each technique was performed by following the manufacturer’s 
recommendations. Protein concentrations were obtained from a standard curve and were 
expressed as ng/mL of eluted GCF. 
 
4.19 Activity assays: 
MMP-13 activity assay (II) 
The MMP-13 activity was measured in aliquots of GCF samples by the “Fluorokine E” 
activity fluorescent assay (R&D Systems, Inc. Minneapolis, USA), according to the 
manufacturer’s recommendations. GCF aliquots and standards were added to the wells, and 
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any MMP-13 present was bound to the immobilised MMP-13 antibody. After washing, a 
fluorogenic substrate linked to a quencher molecule was added, allowing a fluorescent signal 
after cleavage by active MMP-13. The enzyme activity was expressed as ng of the 
fluorescent product (ng FP) per mL of eluate. 
MMP-14 activity assay (III) 
The MMP-14 active enzyme was measured in GCF aliquots using an MMP-14 Biotrak 
activity assay system (GE Healthcare, Amersham, Slough, Berkshire, UK), following the 
manufacturer’s recommendations. Briefly, the standards (MMP-14) and the samples were 
added to a microplate, and MMP-14 was bound to the immobilised MMP-14 antibodies in the 
wells. The assay used the proform of a detection enzyme with an artificial sequence that was 
activated by captured active MMP-14 and was measured by adding a specific chromogenic 
peptide substrate and read via a microplate spectrophotometer at 405 nm. The total 
(active+proenzyme) MMP-14 in the samples was also measured by adding 
aminophenylmercuric acetate (APMA), (Sigma, St. Louis, MO, USA). Results were 
expressed as ng/mL of eluate. 
Gelatin zymography (II) 
To determine the MMP-9 and -2 activities, aliquots of supernatants from explant cultures 
were run under non-reducing denaturing conditions on 10% polyacrylamide gels containing 1 
mg/mL gelatine (Merck, Darmstadt, Germany); the gels were washed, incubated in 
developing buffer (20 mM Tris pH 7.4 and 5 mM CaCl2) for 17 h, stained and destained. The 
densitometric analysis was performed as described above and results were expressed as 
arbitrary units of density/mL of supernatant. 
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4.2 Animal studies (IV) 
4.21 Animals 
Study animals and specimens were previously manipulated and prepared by Kuula et al. 
(2009) and included 14-week-old male mice maintained in the experimental animal facilities 
of the University of Oulu, Oulu, Finland. The MMP-8-/- knock out (KO) mice from a mixed 
C57BL/6J/129 background (Balbin et al., 2003) and wild-type (WT) mice littermates, 
resulting from intercrossing of heterozygous mice, were included as controls (Balbin et al., 
2003; Korpi et al., 2008; Korpi et al., 2009). Experiments were conducted in accordance with 
the guidelines of the Animal Experimentation Committee of University of Oulu, Oulu 
Finland. 
 
4.22 Induction of experimental periodontitis 
The experimental groups were assigned as follows: WT-infected (n = 10), WT uninfected (n 
= 8), MMP-8 KO infected (n = 12) and MMP-8 KO uninfected (n = 10) (total N = 40). 
Statistical power analysis, based on a pilot study, was previously performed to determine an 
appropriate sample size. 
To eliminate the native flora from the oral cavity, the mice received 20 mg of kanamycin and 
20 mg of ampicillin in 1mL of sterile water twice daily for 3 days and were then allowed to 
clear it from their systems for 4 days prior to oral inoculation with P. gingivalis (strain 
ATCC33277, American Type Culture Collection). A suspension of approximately 0.1-0.2 mL 
of carboxymethyl cellulose with viable P. gingivalis was swabbed intraorally twice a day for 
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3 days, while negative controls received saline. Mice were killed 30 days after the last 
inoculation by cervical dislocation. The skulls were processed for routine HE and 
immunohistochemical analyses. 
4.23 Immunohistochemistry 
Immunohistochemistry was used to analyse the cytokine presence and levels with rabbit anti-
LIX/CXCL5 (Preprotech, EC, London, U.K.), mouse anti-SDF-1/CXCL12 (R&D Systems, 
Inc. Minneapolis, USA) and goat anti-RANKL (R&D Systems, Inc. Minneapolis, USA) 
antibodies; the presence of the studied cytokines was visualised with a Vectastain Elite ABC 
kit (Vector Labs, Burlingame, CA, USA) using biotinylated secondary antibodies and 3-
amino-9-ethylcarbazole (AEC) as chromogen. Randomly selected images were acquired using 
an Olympus BX61 microscope with an Olympus DP50 camera, as well as UPlanFl 40x/0.75 
NA and 20x/0.50 NA objectives. Immunoreactive mesenchymal cells from total cells and the 
immunoreactive area of gingival epithelia from total gingival epithelia, respectively, were 
analysed with a macro written for the public domain ImageJ software (Rasband, W.S., 
ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, 
http://rsb.info.nih.gov/ij/, 1997-2009). 
 
4.3 Statistical analysis 
 
Differences regarding dichotomic measurements were analysed by a chi-squared test; 
comparisons between two related groups, using a paired t-test or Wilcoxon test depended on 
the data distribution, whereas comparisons between two unrelated groups were analysed with 
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an unpaired t-test and Mann-Whitney test. An ANOVA with Bonferroni´s or Tukey`s post 
hoc test was performed for >2 independent groups and for comparisons with parametric data 
distribution. Pearson`s or Spearman’s correlation was applied to determine the association 
between variables. Comparisons between active, inactive –from progressive subjects– and 
healthy subjects were analysed separately using the linear mixed model. In each model 
(MMP, ICTP, TIMP), comparisons between groups were performed with an F-test, and 
denominator degrees of freedom were computed by the Kenward method, and further 
correction for the multiple testing was applied using the Tukey adjustment. 
A p value <0.05 was considered statistically significant. Statistical analyses were performed 
with Stata V10 software (StataCorp, Collage Station, TX, USA) and SAS proc Mixed (SAS 





5.1 Human studies 
5.11 Clinical parameters (I, II, III) 
Clinical features from periodontitis patients versus controls differed only regarding to 
periodontal clinical parameters. In periodontitis patients, all clinical parameters improved 
significantly after conventional periodontal treatment. 
 
5.12 GCF volumes and total protein concentrations in healthy and progressive 
periodontitis subjects (I) 
Mean GCF volumes and total protein concentration significantly increased in progressive 
periodontitis patients (n = 21 actives and 21 inactives), when compared with healthy subjects 
(n = 11). The mean GCF volumes were similar among active and inactive sites and the mean 
total protein concentrations were significantly different among all groups, decreasing from 
active sites to healthy ones (Table 1.). 
 
5.13 MMP-13 and TIMP-1 molecular forms in healthy and progressive periodontitis 
subjects (I) 
MMP-13 detection was limited to disease GCF as immunoreactive bands of ~60 kDa 
(proform), 56 kDa (intermediate forms), 48 kDa (active enzyme) and fragments (25-35 kDa); 
TIMP-1 was identified as a 34 kDa immunoreactive protein. 
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5.14 MMP-13, ICTP and TIMP-1 levels in healthy and progressive periodontitis 
subjects (I, II) 
MMP-13 protein levels were undetected in healthy GCF by either immunodot blot or 
immuno-Western blot, whereas all periodontitis sites showed positive results. A comparison 
of MMP-13 and TIMP-1 levels in tissue samples and GCF from active and inactive sites from 
progressive periodontitis subjects by immunodot blotting showed no significant differences 
among sites. Nevertheless, a trend to a positive correlation between TIMP-1 and MMP-13 
was found in inactive sites (r = 0.61, p = 0.2), compared with an inverse correlation for active 
sites (r = -0.5, p = 0.35). 
Regarding MMP-13 activity, even if there was a trend to increase from healthy to active sites 
in progressive patients, significant differences were found only for active sites that displayed 
the highest MMP-13 activity, compared with inactive and healthy sites. Similar changes were 
found for ICTP levels that showed the highest levels (p<0.05) in active sites versus inactive 
ones and healthy controls. TIMP-1 was not detected in all samples and percentages of 
detection, as well as mean levels, increased in healthy GCF compared with active and inactive 
sites, but the difference was significant only for percentages of detection (Table 1.). 
 
5.15 MMP-13 and gelatinase activation in periodontitis-affected gingival tissue (II) 
Adding of exogenous recombinant MMP-13 to gingival explants from periodontitis patients 
resulted in significantly increased proMMP-9 activation at 1 h and 24 h after enzyme addition 
and a trend towards higher MMP-2 activation rates. Almost no detectable active MMP-9 was 
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seen, despite the addition of MMP-13 when the CL-82198 MMP-13 selective inhibitor was 
used. Additionally, a strong positive correlation was found between the active MMP-9 and 
MMP-2 enzyme forms (r = 0.84, p<0.0001). 
 
5.16 MMP-8, MMP-14 and MPO molecular forms in GCF from progressive 
periodontitis (III) 
MMP-8 immunoreactivities were found as ~85 and ~64 kDa bands for pro and active PMN 
isoforms, respectively, ~55 and ~48 kDa for mesenchymal proform and active enzymes, 
respectively, for complexes of  ≥100 kDa and fragments ≤  46 kDa. MMP-14 soluble forms 
were found as ~50 kDa bands, whereas complexes and fragments were also detected. MPO 
immunoreactivities were identified at ~75, 90, 130 and 160 kDa. All enzyme forms were 
detected in all screened samples from both active and inactive sites. 
 
5.17 MMP-8, MMP-14 and MPO levels in GCF from progressive periodontitis at 
baseline and after treatment (III) 
Densitometric analysis of MMP-8 immunoreactivities demonstrated that PMN-type MMP-8 
forms predominated over the mesenchymal forms. Among all MMP-8 forms, active enzymes 
and the percentages of activation for both PMN and mesenchymal isotypes tended to increase 
at inactive sites, whereas all MMP-14 forms tended to increase at active sites, except for the 
complexes. Similarly, the analysis of protein levels for MMP-8, total and active MMP-14 and 
MPO demonstrated that only active and total MMP-14 levels tended to increase in active 
sites, but none of the differences were significant (Table 1.). 
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The total levels of MMP-8 and MPO were measured in progressive periodontitis sites at 
baseline and after periodontal treatment, showing significant reductions, except for MMP-8 in 
active sites. 
5.18 Association between MPO levels and MMP-8 in GCF (III) 
A positive correlation was found between total MPO with total MMP-8 (r = 0.74 inactives; r 
= 0.92 actives, p<0.05) and with its active forms (PMN isoform, r = 0.77; mesenchymal 
isoform, r = 0.69; p<0.05). This association was lost in inactive sites after periodontal 
treatment, but still remained for active sites. 
 
5.2 Animal studies: P. gingivalis-induced experimental periodontitis in 
MMP-8 null mice and controls (IV) 
 
Typical histopathological changes associated with chronic periodontitis were observed in P. 
gingivalis-infected mice. No differences were found in cytokine distribution by tooth 
localisation (p>0.05). 
5.21 LIX/CXCL5 expression 
LIX/CXCL5 was consistently expressed in the epithelia of gingival papilla from all studied 
mice; it was significantly reduced in the P. gingivalis-infected KO group compared with 
infected wild-type controls, with levels comparable to non-infected mice (Table 2.). 
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5.22 SDF-1/CXCL12 and RANKL expression 
SDF-1/CXCL12 and RANKL expression patterns were more ubiquitous in periodontal tissues 
than LIX/CXCL5, but were almost restricted to P. gingivalis-infected groups. Moreover, the 
frequencies of detection for both cytokines were significantly higher in infected groups 
compared with uninfected ones (Table 2.). SDF-1/CXCL12 was primarily expressed in 
periodontal ligaments and the strongest staining was localised to the vascular channels close 
to areas of alveolar bone resorption. The most striking RANKL expression was localised to 
the periodontal ligament and osteoclasts surrounding the alveolar crest. SDF-1/CXCL12 and 
RANKL levels showed no significant differences between KO and WT mice, but a significant 
positive correlation was found between both cytokines in all study groups (r = 0.40, p=0.01). 
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Table 1. Summary table of examined potential biomarkers in GCF from progressive 
periodontitis patients at baseline and healthy subjects 
  Active Inactive Controls N p 
GCF mean volume 
(µL) 
0.94±0.21 0.92±0.18 0.22±0.13 53 <0.05 
GCF Mean protein 
concentration (mg/mL) 
0.68±0.059 0.37±0.059 0.11±0.081 53 <0.05 
MMP-13 activity  
(ng FP/mL) 
1.49±0.46 1.17±0.20 1.03±0.18 53 <0.05 
ICTP  
(ng/mL) 
0.49±0.21 0.31±0.15 0.24±0.13 53 <0.05 
TIMP-1  
(% cases) 
47.60% 76.20% 100% 53 <0.05 
TIMP-1  
(ng/mL) 
0.319±0.09 0.286 ±0.10 0.673± 0.49 53 >0.05 
MMP-8  
(ng/mL) 
119.35 (196.92) 153.86 (185.52) --- 50 >0.05 
PMN MMP-8 active 
(au/mL) 
0.52 (0.80) 0.39 (0.92) --- 28 >0.05 
Mesenchymal MMP-8 
active (au/mL) 
0.45 (0.36) 0.15 (0.55) --- 28 >0.05 
MPO  
(ng/mL) 
287.94 (675.79) 660.05 (789.81) --- 50 >0.05 
MMP-14 active enzyme 
(ng/mL) 
6.89 (3.31) 5.57 (7.55) --- 50 >0.05 
MMP-14 total  
(ng/mL) 
18.80 (33.07) 16.82 (15.22) --- 50 >0.05 
 
Values expressed as means ± SD or medians (IQR). GCF mean volume: Controls vs. 
inactives and actives p<0.05; inactives vs. actives p>0.05; GCF mean protein 
concentration: Actives vs. inactives and healthy p<0.05; Inactives vs. healthy p<0.05; 
MMP-13 activity: actives vs. inactives and controls p<0.05; inactives vs. healthy, p>0.05; 
ICTP levels: actives vs. inactives and controls p<0.05; inactives vs. healthy, p>0.05. 
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Table 2. LIX/CXCL5, SDF-1/CXCL12 and RANKL expression in MMP-8 knock out 
and wild-type mice infected with P. gingivalis and controls 
 WT+Pg KO+Pg WT-Pg KO-Pg p 
LIX/CXCL5 0.366±0.153* 0.222±0.175* 0.276±0.121 0.183±0.116* <0.005 
SDF-1/CXCL12 (%) 54.5 41.1 16.3 7.3 <0.005 
RANKL (%) 80.0 65.0 12.8 6.4 <0.005 
 
Results expressed as means ±SD of total positive area/total area per field or percentage (%) of 
immunostained sites from total examined sites. Asterisks represent the group pairs that 






Periodontitis is described as a multifactorial, irreversible and cumulative condition, initiated 
and propagated by bacteria and host factors (Buduneli and Kinane, 2011). Pathologically 
enhanced expression and activation of host MMPs induced by bacterial infection and 
cytokines are well-characterised features in chronic periodontitis. The resultant unhampered 
proteolysis might lead to periodontal damage and the perpetuation of the inflammatory 
response, favouring disease progression (Kessenbrock et al., 2010; Sorsa et al., 2006). 
Chronic periodontitis progression is a continuous process that undergoes dynamic periods 
of activity and remission (Jeffcoat and Reddy, 1991; Kinane, 2001). Accordingly, 
periodontal support is lost during short, acute episodes of disease activity or bursts. Though 
the hallmark of disease activity is the loss of soft or hard tissue attachment to the tooth, 
longitudinal recording of clinical attachment by the tolerance method has been the most 
commonly used approach to diagnose progressive periodontal disease (Reddy et al., 1997). 
Consequently, analysis of GCF samples from active versus inactive progressive sites can 
provide a closer view of the proteolytic events involved in supporting tissue breakdown and 
surrogate biomarkers. 
In this study, we show differences in protein composition among active, inactive and 
healthy sites, pointing towards increased proteolysis in the former sites. Enhanced 
collagenase levels and activity were found in chronic periodontitis and was associated with 
disease progression. Furthermore, enhanced collagenase-mediated proteolytic cascades 
seemed to interact with the immune-inflammatory components during the initiation and/or 
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progression of periodontitis. Based on these findings, GCF collagenase signatures can 
potentially be useful as biomarkers for disease progression. 
GCF has widely been regarded as a key source of potential biomarkers in periodontitis. 
During periodontitis, GCF shifts from a transudate to an exudate; consequently, the GCF 
volume and composition change as result of protein extravasation from serum, local 
synthesis and release of catabolic products derived from periodontally diseased tissues 
(Adonogianaki et al., 1996; Curtis et al., 1990; Oringer et al., 2002). In the present study, 
the analysis of volume and total protein content in GCF demonstrated differences between 
healthy and chronic periodontitis subjects, as expected. During progressive periodontitis, 
we found that GCF from active sites showed similar volumes, but nearly as twice as much 
total protein concentration as inactive sites. In accordance with our results, increases up to 
fivefold in GCF volume have previously been reported in subjects affected by gingivitis 
and periodontitis, compared with healthy controls (Pisano et al., 2005). During chronic 
periodontitis, inflammatory changes in both active and inactive sites were reflected in 
increased GCF volume and total protein concentration when compared with healthy sites; 
Nonetheless, active sites were expected to undergo a current periodontal tissue breakdown 
compared with their inactive counterparts; this breakdown can be reflected in the increased 
protein content in GCF due to the release of protein mediators and periodontal matrix 
breakdown products, where collagens type I and III are the main constituents of both 
periodontal ligament and alveolar bone (Alpagot et al., 2001). GCF volume and protein 
content varied considerably according to the periodontal status. Because most of protein 
and volume variations in GCF from healthy and periodontitis sites can be attributed to the 
increasing of vascular permeability triggered by local inflammatory process, the current 
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results confirm that the more sensitive method of standardisation was through the 
expression of target proteins under fixed periods (30 s) of fluid collection (Golub et al., 
1997; Lamster and Novak, 1992). 
The initial cleavage of periodontal collagens by collagenolytic MMPs is believed to play a 
pivotal role over the loss of periodontal supporting tissues. Conversely, the collagenase 
inhibitor TIMP-1 has been related to connective tissue regeneration (Sorsa et al., 2006). 
Among collagenases, MMP-8 and MMP-13, along with the gelatinase MMP-9, are the 
major MMPs associated with the severity of periodontal disease (Leppilahti et al., 2010; 
Sorsa et al., 2004; Sorsa et al., 2006; Teles et al., 2008; Tervahartiala et al., 2000). In GCF 
from chronic periodontitis subjects, MMP-8 and MMP-9 are the predominant MMPs, 
whereas MMP-13 comprises only 3-4% of total collagenases (Kiili et al., 2002; 
Tervahartiala et al., 2000) and even less or no MMP-1 has been detected (Golub et al., 
1997). 
MMP-13 was not detected in healthy GCF by immunoblot, but MMP-13 activity levels 
could be detected in both, healthy and disease GCF. MMP-13 expression is highly 
restricted to those situations in which rapid collagen turnover is required (Rydziel et al., 
2000). Despite the fact that MMP-13 levels did not differ among active and inactive sites, 
the MMP-13 activity was significantly higher in active sites compared with inactive and 
healthy ones. In accordance with these findings, active sites showed a tendency for MMP-
13 levels to increase along with decreasing levels of TIMP-1, displaying a negative 
correlation. These data suggested that periodontitis might be associated with augmented 
levels of MMP-13, whereas disease activity might derive, in part, from an unbalance 
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involving limited MMP-13 inhibition and a higher enzyme activation rate, resulting in 
increased MMP-13 activity. 
In progressive periodontitis, MMP-13 was primarily detected as a band of 56 kDa that 
could represent a partially activated form derived from the 60 kDa proenzyme (Golub et al., 
1997; Hernandez et al., 2006); some faint 48 kDa bands, corresponding to fully active 
forms, and partially degraded fragments with molecular weight between 35 and 25 kDa 
(Ilgenli et al., 2006). ProMMP-13 can be activated, among other MMPs, such as MMP-2 
and MMP-13 itself, by MMP-14 in the presence of TIMP-1. A first cleavage at the Gly35-
Ile36 site generates the intermediate fragment, while a second N-terminal Tyr85 cleavage 
generates the fully active enzyme (Knauper et al., 1996) that is highly unstable, generating 
fragments of low molecular weight (Knauper et al., 1997a). 
Similarly to MMP-13 activity, active sites showed increased ICTP levels, assumed to be 
primarily generated from bone collagen by MMPs (Fuller et al., 2007), when compared 
with inactive and healthy sites. The addition of MMP-13 to diseased gingival tissue explant 
cultures resulted in an enhanced proMMP-9 activation rate. Thus, MMP-13 might influence 
periodontitis progression by contributing to bone catabolism, either directly through its 
collagenolytic activity or indirectly through the enhancement of MMP-9 activation. 
Previously, an association between reduced levels of TIMP-1, higher total collagenase and 
gelatinase activity and the severity of clinical parameters was reported in periodontitis 
patients, along with significant reductions after periodontal treatment (Pozo et al., 2005). 
As collagenolytic and gelatinolytic activities are cooperative and sequential during the 
degradation of native collagen, the enhancement of MMP-9 activation by MMP-13 in 
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periodontitis might represent a pathogenic mechanism to potentiate and even perpetuate 
supporting tissue destruction. 
Besides sulcular epithelial cells, macrophage-like cells, fibroblasts and plasma cells, MMP-
13 is expressed by bone osteoblasts, where it is thought to participate in bone homeostasis 
(Hernandez et al., 2006; Rydziel et al., 2000). Additionally, MMP-13 is capable of 
activating proMMP-9 produced by osteoclasts in vitro (Rydziel et al., 2000). Therefore, a 
combination of MMP activity could reflect the release of ICTP fragment to GCF (Golub et 
al., 1997). The regulatory role of MMP-13 over other MMPs, such as MMP-9, implies that 
minimal changes in MMP-13 levels or activity can elicit proteolytic downstream cascades 
that might partially explain periodontitis progression. A previous clinical trial tested a sub-
antimicrobial dose doxycycline (SDD) treatment in post-menopausal women exhibiting 
periodontitis and systemic osteopenia during a two-year follow-up period (Golub et al., 
2008). The improvement of clinical parameters in the SDD group was associated with 
reduced total collagenase activity and a decrease of the bone resorption fragment ICTP. 
Interestingly, a strong positive correlation between GCF ICTP and total collagenase activity 
was found, supporting a role for collagenases in bone loss and thereby in disease 
progression, which can be reflected in GCF. 
MMP-8 corresponds to the main collagenase in GCF (Golub et al., 1997), and its active 
form has previously been associated with the conversion of gingivitis to periodontitis and 
progression of established periodontitis (Mantyla et al., 2006). In the current study, an 
increasing trend was seen for the MMP-8 enzyme in active sites versus inactive sites, but it 
was limited to the active forms from both, neutrophil and mesenchymal isotypes and their 
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respective percentages of activation, whereas the neutrophil MMP-8 was the predominating 
isotype (Golub et al., 1997; Golub et al., 2008). 
The main source of latent MMP-8 corresponded to neutrophils and could be activated 
during periodontal inflammation by reactive oxygen species (ROS) and by microbial and 
host-derived proteases (Sorsa et al., 1992), representing oxidative and proteolytic activation 
pathways, respectively. Furthermore, ROS can oxidatively inactivate TIMP-1 (Sorsa et al., 
2006). Previous in vitro results have shown that both, MPO-produced hypochlorous acid 
and MMP-14-mediated proteolysis can activate proMMP-8 (Holopainen et al., 2003; Saari 
et al., 1990). Accordingly, we found a significantly strong to moderate positive correlation 
between total MMP-8 levels, active MMP-8 forms and MPO in both, active and inactive 
sites at baseline; scaling and root planning (SRP) resulted in significant MPO and MMP-8 
reductions in all groups and the loss of MPO/MMP-8 association in treated inactive sites. 
Nevertheless, the MMP-8/MPO association remained in treated active sites, despite the 
reduced sample size. Conversely, no association was found between active forms of MMP-
8 and MMP-14, suggesting that the oxidative pathway might represent the most important 
activation mechanism for MMP-8 during periodontitis progression. 
Consistent with our findings, it has been reported that repeatedly elevated GCF MMP-8 
levels detected during the maintenance phase after SRP was associated with a lack of 
improvement in clinical parameters (Mantyla et al., 2006) and increased odds of subsequent 
attachment loss. No association was found between MMP-8 levels and alveolar bone loss in 
the latter study (Reinhardt et al., 2010). Thus, sustained MMP-8 levels might reflect 
periodontal breakdown, inflammation or sites at risk of further periodontal loss (Hernandez 
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et al., 2010; Sorsa et al., 2010). A strong MMP-8/MPO association after periodontal 
treatment might reflect the persistent activation of MMP-8 and the need for further therapy. 
In addition to its classical collagenolytic properties, MMP-8 might influence the immune 
response through proteolytic processing of non-matrix bioactive molecules, modifying their 
bioavailability and biological activity (Sorsa et al., 2004; Tester et al., 2007; Van Lint et al., 
2005). Since the recent developments of MMP-8 deficient mouse models, new concepts 
regarding the roles of MMP-8 are emerging. MMP-8 deficient mice have been found to 
display an altered neutrophil infiltration (Gutierrez-Fernandez et al., 2007; Korpi et al., 
2009). Furthermore, recent reports have demonstrated associations between MMP levels 
and activity with changes in processed forms of cytokines and in their protein levels 
(Gutierrez-Fernandez et al., 2007; Nilsson et al., 2009).  
A previous study had been conducted in a P. gingivalis-induced periodontitis MMP-8-
deficient mice model, where a more destructive periodontitis phenotype in MMP-8-/- 
animals was reported. In the current study, we complement these results by demonstrating 
that MMP-8 KO mice exhibited significantly reduced levels of chemokine LIX/CXCL5 
compared with their WT counterparts at the periodontal-oral interface. It is plausible that, 
given the potent chemoattractant effects of LIX/CXCL5 over PMN (Kebschull et al., 2009), 
these mice displayed impaired neutrophil infiltration to periodontal tissues, which might 
explain at some level the extensive alveolar loss observed in these mice. Nevertheless, 
given the pleiotropic and redundant character of cytokines, further studies are needed. At 
physiological levels, MMP-8 might be protective for periodontal tissues, whereas 
pathologically elevated MMP-8 levels or activity might result in excessive periodontal 
breakdown, explaining the apparently controversial results obtained from the clinical 
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studies and animal models. Additionally, a significantly higher frequency of detection for 
the cytokines RANKL and SDF-1/CXCL12 was found in P gingivalis-infected mice, 
irrespectively from the MMP-8 genotype, suggesting that they might play a role in the 
initiation and/or progression of periodontitis. 
In summary, the results of the current study suggest that collagenases MMP-8 and -13 are 
involved in periodontitis progression and that their pathogenic mechanism is not limited to 
direct periodontal matrix degradation; rather, they form complex networks involving the 
immune response, oxidative stress and proteinase cascades. The identification of these 
networks in biological samples, such as GCF, will contribute to the development of chair 
side/point of care diagnostic methods to complement clinical practice, to monitor the 





1. Chronic periodontitis subjects show increased GCF volume, total protein concentration and 
MMP-13 detection compared to healthy controls. 
2. Active sites from progressive periodontitis subjects are associated with higher MMP-13 
activity and ICTP levels, and reduced detection of the inhibitor TIMP-1 compared with 
inactive sites. An unbalance between MMP-13 activation vs. inhibition might be involved 
in soft periodontal tissue and bone catabolism that characterizes active disease. 
3. MMP-13 enhances proMMP-9 activation rate in gingival tissue from subjects affected with 
chronic periodontitis. This MMP interaction might further potentiate proteolytic-mediated 
tissue destruction during disease. 
4. MPO and MMP-8 positive correlation and levels associate with progressive sites at 
baseline and after periodontal treatment.  
5. Experimentally-induced periodontitis is characterized by higher SDF-1/CXCL12 and 
RANKL detection in periodontitis-affected tissues. Thus, they might play a central role in 
disease pathogenesis and/or progression. 
6. The levels of the neutrophil-chemoattractant LIX/CXCL5 are reduced in infected MMP-8 
null mice vs. wild type mice and might result in reduced neutrophil chemotaxis at the oral-
periodontal interface and enhanced severity of periodontal disease in MMP-8 null mice. 
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7. Targeting of MMP-13/ICTP/MMP-9 and MMP-8/MPO interactions in GCF might be 
potentially useful to screen sites at risk of progression, evaluate response to treatment and 
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